Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples